Neucell Pharma

NeuCell Therapeutics is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases and central nervous system injuries through in vivo cell transdifferentiation. Founded by Dr. Gong Chen, the company utilizes a proprietary platform to convert reactive glial cells, such as astrocytes, into functional neurons directly within the brain or spinal cord. This approach leverages both gene therapy, using AAV vectors to deliver transcription factors like NeuroD1, and small molecule cocktails to induce neural regeneration. NeuCell's pipeline targets high-unmet-need indications including Parkinson's disease, stroke, and Huntington's disease. By regenerating lost neurons and restoring neural circuits, the company aims to provide curative solutions for conditions that currently only have symptomatic treatments. NeuCell is headquartered in Suzhou, China, with research roots at Pennsylvania State University.